Risk-reducing salpingo-oophorectomy and ovarian C screening in 1077 women after BRCA testing

JAMA Internal Medicine

Volumn 173, Issue 2, 2013, Pages 96-

  Mannis, Gabriel N ^a   Fehniger, Julia E ^a   Creasman, Jennifer S ^b,c   Vanessa, L M A S ^a   Beattie, Mary S ^c  

^a Cancer Risk Program   (United States)

^b Department of Obstetrics   (United States)

^c UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA PROTEIN; CA 125 ANTIGEN; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SCREENING; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC COUNSELING; GENETIC SCREENING; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

ADULT; CA-125 ANTIGEN; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS; SALPINGECTOMY;

EID: 84873433004     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/2013.jamainternmed.962     Document Type: Article

References (36)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Oncol 2007;25(11):1329-1333 (Pubitemid 46706879)
3. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. B ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646 (Pubitemid 37310920)
4. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction esti associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 carriers. J Natl Cancer Inst. 2009;101(2):80-87
5. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing s BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (9): 967-975
6. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-ooph women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1
7. Schwartz MD, Kaufman E, Peshkin BN, et al. Bilateral prophylactic ooph ovarian cancer screening following BRCA1/BRCA2 mutation testing. J C Oncol. 2003;21(21):4034-4041 (Pubitemid 46606219)
8. Uyei A, Peterson SK, Erlichman J, et al. Association between clinical cha risk-reduction interventions in women who underwent BRCA1 and BRCA single-institution study. Cancer. 2006;107(12):2745-2751 (Pubitemid 44937026)
9. Madalinska JB, Van Beurden M, Bleiker EM, et al. Predictors of prophyla salpingo-oophorectomy compared with gynecologic screening use in BRC carriers. J Clin Oncol 2007;25(3):301-307 (Pubitemid 350003018)
10. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al; Hereditary Breast C Study Group. International variation in rates of uptake of preventive opti and BRCA2 mutation carriers. Int J Cancer. 2008;122(9):2017-2022 (Pubitemid 351441190)
11. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time cours predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers. 2009;13(1):51-56
12. American Cancer Society. Can ovarian cancer be found early? Updated Oc http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovariandetection. Accessed January 23, 2012
13. American College of Obstetricians and Gynecologists Committee on Gyne Practice. Committee opinion No. 477: the role of the generalist obstetricia in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;11
14. Gladstone CQ. Screening for ovarian cancer. In: Canadian Task Force on Health Examination, ed. Canadian Guide to Clinical Preventive Health C ON: Minister of Public Works and Government Services Canada; 1994:87
15. National Comprehensive Cancer Network Practice Guidelines in Oncology familial high-risk assessment: breast and ovarian. Updated January 2011. https://subscriptions.nccn.org/gl-login. aspx?
16. Return URL= http://www.nccn.org/professionals/physician-gls/pdf/gen Accessed January 23, 2012
17. US Preventive Services Task Force. Screening for ovarian cancer: recomm statement. Am Fam Physician. 2005;71(4):759-762
18. Hermsen BB, Olivier RI, Verheijen RH, et al. No efficacy of annual gynae screening in BRCA1/2 mutation carriers; an observational follow-up study Cancer. 2007;96(9):1335-1342 (Pubitemid 46685786)
19. Van Nagell JR Jr, De Priest PD, Ueland FR, et al. Ovarian cancer screenin transvaginal sonography: findings of 25, 000 women screened. Cancer. 20(9):1887-1896
20. Buys SS, Partridge E, Black A, et al; PLCO Project Team. Effect of screeni cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Canc randomized controlled trial. JAMA. 2011;305(22):2295-2303
21. Van Nagell JR Jr, Miller RW, De Simone CP, et al. Long-term survival of w epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol. 2011;118(6):1212-1221
22. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo J Cruger DG. Annual surveillance by CA125 and transvaginal ultrasound for in both high-risk and population risk women is ineffective. BJOG. 2007;1 1509
23. Gaarenstroom KN, Van der Hiel B, Tollenaar RA, et al. Efficacy of screening wom of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Can (suppl 1) 54-59
24. Laframboise S, Nedelcu R, Murphy J, Cole DE, Rosen B. Use of CA-125 an high-risk women. Int J Gynecol Cancer. 2002;12(1):86-91
25. Van der Velde NM, Mourits MJ, Arts HJ, et al. Time to stop ovarian cance BRCA1/2 mutation carriers? Int J Cancer. 2009;124(4):919-923
26. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilities for b susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998;62(1):145
27. Lee R, Beattie M, Crawford B, et al. Recruitment, genetic counseling, and for underserved women at a public hospital. Genet Test. 2005;9(4):306-3
28. Claritas. The Nielsen Co: income producing assets and net worth profiles: wealth by segment targeting. Updated 2008. http://www.clusterstaging.claritas. com/collateral/segmentation/targesegment-f3026.pdf. Accessed January 23, 2012
29. Manchanda R, Burnell M, Abdelraheim A, et al. Factors influencing upta of risk reducing salpingo-oophorectomy in women at risk of familial ovari competing risk time to event analysis. BJOG. 2012;119(5):527-536 doi: 10.1111/j.1471-0528.2011.03257.x
30. Sidon L, Ingham S, Clancy T, et al. Uptake of risk-reducing salpingo-oop women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake i affected by breast cancer and older women. Br J Cancer. 2012;106(4):775
31. Schwartz MD, Isaacs C, Graves KD, et al. Long-term outcomes of BRCA1 testing: risk reduction and surveillance. Cancer. 2012;118(2):510-517
32. Lu K, Kauff N, Powell CB, et al; American College of Obstetricians and Gy ACOG Committee on Practice Bulletins-Gynecology; ACOG Committee on Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: here and ovarian cancer syndrome. Obstet Gynecol. 2009;113(4):957-966
33. Kauff ND, Mitra N, Robson ME, et al. Risk of ovarian cancer in BRCA1 an mutation-negative hereditary breast cancer families. J Natl Cancer Inst. 2(18):1382-1384
34. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of indi germline mutations in BRCA1 and BRCA2: analysis of 10, 000 individuals. Oncol. 2002;20(6):1480-1490 (Pubitemid 34260526)
35. Press DJ, Sullivan-Halley J, Ursin G, et al. Breast cancer risk and ovariec hysterectomy, and tubal sterilization in the Women's Contraceptive and R Experiences Study. Am J Epidemiol. 2011;173(1):38-47
36. Baldwin LM, Trivers KF, Matthews B, et al. Vignette-based study of ovar screening: do US physicians report adhering to evidence-based recommen Intern Med. 2012;156(3):182-194